News Roche licenses Innovent ADC that could challenge Amgen drug Roche licenses rights to a DLL3-targeted ADC from China's Innovent, hoping to bring a competitor to Amgen's lung cancer therapy Imdelltra to market.
News Early cancer diagnoses reach record level in NHS Early cancer diagnoses have risen to record levels in England, says NHS, but long waiting times for treatment threaten to undermine the gains.
News Ottimo raises $140m for its PD-1/VEGF cancer drug Ottimo raises $140m for PD-1 and VEGF-targeting jankistomig, which the startup says is differentiated from bispecific antibodies in the class.
Oncology Sponsored 12 Questions with Mimi Huizinga Dr Mimi Huizinga is Vice President, Oncology Medical Affairs, Lung Cancer at AstraZeneca.
News End of the line for MSD's TIGIT, LAG-3 cancer drugs MSD has stopped development of anti-TIGIT antibody vibostolimab and anti-LAG-3 antibody favezelimab, blowing a hole in its immuno-oncology pipeline.
News FDA dents J&J's blockbuster hopes for Rybrevant FDA has sent a complete response letter to J&J, denying approval of its subcutaneous version of lung cancer therapy Rybrevant.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.